PortalPublikationenPhase III study of doxorubicin/cyclophosphamide with concomi...

Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.

Standard

Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. / Eiermann, Wolfgang; Pienkowski, Tadeusz; Crown, John; Sadeghi, Saeed; Martin, Miguel; Chan, Arlene; Saleh, Mansoor; Sehdev, Sandeep; Provencher, Louise; Semiglazov, Vladimir; Press, Michael; Sauter, Guido; Lindsay, Mary-Ann; Riva, Alessandro; Buyse, Marc; Drevot, Philippe; Taupin, Henry; Mackey, John R.

in: J CLIN ONCOL, Jahrgang 29, Nr. 29, 29, 2011, S. 3877-3884.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Eiermann, W, Pienkowski, T, Crown, J, Sadeghi, S, Martin, M, Chan, A, Saleh, M, Sehdev, S, Provencher, L, Semiglazov, V, Press, M, Sauter, G, Lindsay, M-A, Riva, A, Buyse, M, Drevot, P, Taupin, H & Mackey, JR 2011, 'Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.', J CLIN ONCOL, Jg. 29, Nr. 29, 29, S. 3877-3884. <http://www.ncbi.nlm.nih.gov/pubmed/21911726?dopt=Citation>

APA

Eiermann, W., Pienkowski, T., Crown, J., Sadeghi, S., Martin, M., Chan, A., Saleh, M., Sehdev, S., Provencher, L., Semiglazov, V., Press, M., Sauter, G., Lindsay, M-A., Riva, A., Buyse, M., Drevot, P., Taupin, H., & Mackey, J. R. (2011). Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J CLIN ONCOL, 29(29), 3877-3884. [29]. http://www.ncbi.nlm.nih.gov/pubmed/21911726?dopt=Citation

Vancouver

Eiermann W, Pienkowski T, Crown J, Sadeghi S, Martin M, Chan A et al. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J CLIN ONCOL. 2011;29(29):3877-3884. 29.

Bibtex

@article{686c2217b160427db63bc0c61e41d437,
title = "Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.",
abstract = "Anthracyclines, taxanes, and alkylating agents are among the most active agents in treatment of adjuvant breast cancer (BC), but the optimal schedule for their administration is unknown. We performed an adjuvant trial to compare the sequential regimen of doxorubicin with cyclophosphamide (AC) followed by docetaxel (ie, AC>T) with the combination regimen of TAC.",
keywords = "Adult, Humans, Aged, Female, Middle Aged, Young Adult, Lymphatic Metastasis, Follow-Up Studies, Chemotherapy, Adjuvant, Drug Administration Schedule, Cyclophosphamide/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/*administration & dosage, Breast Neoplasms/*drug therapy/enzymology/pathology, Doxorubicin/administration & dosage, Receptor, Epidermal Growth Factor/*biosynthesis, Taxoids/administration & dosage, Adult, Humans, Aged, Female, Middle Aged, Young Adult, Lymphatic Metastasis, Follow-Up Studies, Chemotherapy, Adjuvant, Drug Administration Schedule, Cyclophosphamide/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/*administration & dosage, Breast Neoplasms/*drug therapy/enzymology/pathology, Doxorubicin/administration & dosage, Receptor, Epidermal Growth Factor/*biosynthesis, Taxoids/administration & dosage",
author = "Wolfgang Eiermann and Tadeusz Pienkowski and John Crown and Saeed Sadeghi and Miguel Martin and Arlene Chan and Mansoor Saleh and Sandeep Sehdev and Louise Provencher and Vladimir Semiglazov and Michael Press and Guido Sauter and Mary-Ann Lindsay and Alessandro Riva and Marc Buyse and Philippe Drevot and Henry Taupin and Mackey, {John R}",
year = "2011",
language = "English",
volume = "29",
pages = "3877--3884",
journal = "J CLIN ONCOL",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "29",

}

RIS

TY - JOUR

T1 - Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.

AU - Eiermann, Wolfgang

AU - Pienkowski, Tadeusz

AU - Crown, John

AU - Sadeghi, Saeed

AU - Martin, Miguel

AU - Chan, Arlene

AU - Saleh, Mansoor

AU - Sehdev, Sandeep

AU - Provencher, Louise

AU - Semiglazov, Vladimir

AU - Press, Michael

AU - Sauter, Guido

AU - Lindsay, Mary-Ann

AU - Riva, Alessandro

AU - Buyse, Marc

AU - Drevot, Philippe

AU - Taupin, Henry

AU - Mackey, John R

PY - 2011

Y1 - 2011

N2 - Anthracyclines, taxanes, and alkylating agents are among the most active agents in treatment of adjuvant breast cancer (BC), but the optimal schedule for their administration is unknown. We performed an adjuvant trial to compare the sequential regimen of doxorubicin with cyclophosphamide (AC) followed by docetaxel (ie, AC>T) with the combination regimen of TAC.

AB - Anthracyclines, taxanes, and alkylating agents are among the most active agents in treatment of adjuvant breast cancer (BC), but the optimal schedule for their administration is unknown. We performed an adjuvant trial to compare the sequential regimen of doxorubicin with cyclophosphamide (AC) followed by docetaxel (ie, AC>T) with the combination regimen of TAC.

KW - Adult

KW - Humans

KW - Aged

KW - Female

KW - Middle Aged

KW - Young Adult

KW - Lymphatic Metastasis

KW - Follow-Up Studies

KW - Chemotherapy, Adjuvant

KW - Drug Administration Schedule

KW - Cyclophosphamide/administration & dosage

KW - Antineoplastic Combined Chemotherapy Protocols/administration & dosage

KW - Breast Neoplasms/drug therapy/enzymology/pathology

KW - Doxorubicin/administration & dosage

KW - Receptor, Epidermal Growth Factor/biosynthesis

KW - Taxoids/administration & dosage

KW - Adult

KW - Humans

KW - Aged

KW - Female

KW - Middle Aged

KW - Young Adult

KW - Lymphatic Metastasis

KW - Follow-Up Studies

KW - Chemotherapy, Adjuvant

KW - Drug Administration Schedule

KW - Cyclophosphamide/administration & dosage

KW - Antineoplastic Combined Chemotherapy Protocols/administration & dosage

KW - Breast Neoplasms/drug therapy/enzymology/pathology

KW - Doxorubicin/administration & dosage

KW - Receptor, Epidermal Growth Factor/biosynthesis

KW - Taxoids/administration & dosage

M3 - SCORING: Journal article

VL - 29

SP - 3877

EP - 3884

JO - J CLIN ONCOL

JF - J CLIN ONCOL

SN - 0732-183X

IS - 29

M1 - 29

ER -